Evidence map›Paper›PMID 35829940›Full record

ArticleInflammopharmacology2022

Trivalent chromium supplementation ameliorates adjuvant induced rheumatoid arthritis through up-regulation of FOXP3 and decrease in synovial Cathepsin G expression.

Sally S Hassouna, Eman Sheta, Inass Zaki, Sahar A Harby, Eman A Allam

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05545020 (Trivalent Chromium as a Treatment for Rheumatoid Arthritis Patients), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05545020 phase2 / phase3completednot on this map

Trivalent Chromium as a Treatment for Rheumatoid Arthritis Patients

TypeinterventionalSponsorAlexandria UniversityRan2022 to 2024Enrolled60ConditionsRheumatoid ArthritisArmsTrivalent chromium versus synthetic and/ or biological DMARDs
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Sally S HassounaInternal Medicine Department, Rheumatology and Immunology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt. sallysaadhassouna@gmail.com.ORCID http://orcid.org/0000-0002-7259-5678
Eman ShetaPathology department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Inass ZakiPathology department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Sahar A HarbyClinical Pharmacology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Eman A AllamMedical Physiology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Alexandria University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRheumatoid arthritis (RA) is a known debilitating autoimmune disease. Immune-suppressants that are used for disease treatment have serious side effects, therefore, trivalent chromium (Cr (III)); which has shown evidence of its influences on some inflammatory pathways and cytokines; was used in this study for the first time to be assessed for its therapeutic effect in RA rat model and was compared to prednisolone in a trial to find a treatment with lesser side effects.

methodsAdult male albino rats were randomly divided into four groups: normal, untreated RA, prednisolone treated RA (1.25 mg/kg/day) and Cr (III) treated RA groups (80 μg/kg/day), induction of RA was done by subcutaneous complete Freund adjuvant injection. Study duration was 4 weeks throughout which arthritis scoring and weight measurement were pursued. Histopathological examination and immunohistochemical FOXP3 assessment were done for joint biopsies. Serum inflammatory markers (interleukin 17, interleukin 10, CRP) and synovial erosive arthritis marker (Cathepsin G) were measured. HDL and non-HDL cholesterol were estimated as well.

resultsCr (III) treatment showed marked clinical and histopathological improvement, also astonishing anti-inflammatory effects (increase in FOXP3 expression and interleukin 10, with decrease in interleukin 17, CRP and synovial Cathepsin G) to the extent that Cr (III) effects on inflammation abolishment were comparable to that of prednisolone and even better at some aspects. Moreover, Cr (III) was protective from side effects, i.e., weight gain and dyslipidemia that were seen with prednisolone treatment.

conclusionsCr (III) is promising in treating RA and it lacks some side effects of accustomed immune-modulatory agents including prednisolone. Further experimental studies and clinical trials should be held to see the efficacy of Cr (III) in different doses and to assess its long term side effects when used for rheumatoid arthritis and other autoimmune diseases treatment.

Indexed as

Arthritis, ExperimentalArthritis, RheumatoidAdjuvants, ImmunologicAnimalsCathepsin GChromiumDietary SupplementsForkhead Transcription FactorsInterleukin-10Interleukin-17MalePrednisoloneRatsUp-RegulationAdjuvants, ImmunologicCathepsin GChromiumForkhead Transcription FactorsInterleukin-10Interleukin-17PrednisoloneCathepsin GFOXP3PrednisoloneRheumatoid arthritisTrivalent chromium

Identifiers

PMID35829940
PMCPMC9700653
OpenAlexW4285087025

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.